121 related articles for article (PubMed ID: 38410594)
21. Evaluation of molecular residual disease in operable non-small cell lung cancer with gene fusions, MET exon skipping or de novo MET amplification.
Fu R; Xiong Y; Cai M; Li F; Chen R; Wu Y; Zhong W
Front Med; 2024 May; ():. PubMed ID: 38805102
[TBL] [Abstract][Full Text] [Related]
22. Initial Report: Personalized Circulating Tumor DNA and Survival in Patients with Resectable Pancreatic Cancer.
Eckhoff AM; Kanu E; Fletcher A; Bao M; Aushev VN; Spickard E; Nussbaum DP; Allen PJ
Ann Surg Oncol; 2024 Mar; 31(3):1444-1446. PubMed ID: 38170407
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
[No Abstract] [Full Text] [Related]
24. Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non-small cell lung cancer patients.
Li H; Ma ZL; Li B; Pan YJ; Xiang JQ; Zhang YW; Sun YH; Hou T; Lizaso A; Chen Y; Li X; Hu H
Cancer Med; 2021 Dec; 10(23):8377-8386. PubMed ID: 34664796
[TBL] [Abstract][Full Text] [Related]
25. Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review.
Verzè M; Pluchino M; Leonetti A; Corianò M; Bonatti F; Armillotta MP; Perrone F; Casali M; Minari R; Tiseo M
Transl Lung Cancer Res; 2022 Dec; 11(12):2588-2600. PubMed ID: 36636413
[TBL] [Abstract][Full Text] [Related]
26. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
27. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
28. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
Zhang JT; Liu SY; Gao W; Liu SM; Yan HH; Ji L; Chen Y; Gong Y; Lu HL; Lin JT; Yin K; Jiang BY; Nie Q; Liao RQ; Dong S; Guan Y; Dai P; Zhang XC; Yang JJ; Tu HY; Xia X; Yi X; Zhou Q; Zhong WZ; Yang XN; Wu YL
Cancer Discov; 2022 Jul; 12(7):1690-1701. PubMed ID: 35543554
[TBL] [Abstract][Full Text] [Related]
30. Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.
Bi Y; Xia C; Zhang X; Liu H
Oncol Lett; 2023 Sep; 26(3):407. PubMed ID: 37600327
[TBL] [Abstract][Full Text] [Related]
31. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
32. Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level.
Batmunkh K; Cho S; Yum S; Kim K; Jheon S
Interact Cardiovasc Thorac Surg; 2020 Jun; 30(6):820-826. PubMed ID: 32221597
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
Clevers MR; Kastelijn EA; Peters BJM; Kelder H; Schramel FMNH
Anticancer Res; 2021 Feb; 41(2):869-876. PubMed ID: 33517292
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.
Fakih M; Sandhu J; Wang C; Kim J; Chen YJ; Lai L; Melstrom K; Kaiser A
JAMA Netw Open; 2022 Mar; 5(3):e221093. PubMed ID: 35258578
[TBL] [Abstract][Full Text] [Related]
35. PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.
Xu J; Pu Y; Lin R; Xiao S; Fu Y; Wang T
Front Med (Lausanne); 2022; 9():822200. PubMed ID: 35308511
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a prospective cohort study.
Arrieta O; Villarreal-Garza C; Martínez-Barrera L; Morales M; Dorantes-Gallareta Y; Peña-Curiel O; Contreras-Reyes S; Macedo-Pérez EO; Alatorre-Alexander J
BMC Cancer; 2013 May; 13():254. PubMed ID: 23697613
[TBL] [Abstract][Full Text] [Related]
37. Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.
Hsu WH; Huang CS; Hsu HS; Huang WJ; Lee HC; Huang BS; Huang MH
Ann Thorac Surg; 2007 Feb; 83(2):419-24. PubMed ID: 17257963
[TBL] [Abstract][Full Text] [Related]
38. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer.
Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP
Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823
[TBL] [Abstract][Full Text] [Related]
39. Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer.
Shen H; Jin Y; Zhao H; Wu M; Zhang K; Wei Z; Wang X; Wang Z; Li Y; Yang F; Wang J; Chen K
BMC Med; 2022 Dec; 20(1):480. PubMed ID: 36514063
[TBL] [Abstract][Full Text] [Related]
40. Survival Prediction and Adjuvant Chemotherapy Based on Tumor Marker for Stage IB Lung Adenocarcinoma.
Wang Y; Zheng D; Chen T; Zhang J; Yao F; Chen H
Ann Thorac Surg; 2020 Mar; 109(3):927-937. PubMed ID: 31614135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
